Most Recent Articles by Brandon May
Investigators sought to determine the incidence of benzodiazepine and Z-drug initiation and predictors of long-term use in patients with bipolar disorder.
A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.
Patients with clozapine-resistant schizophrenia who are treated with adjuvant sodium benzoate demonstrate improvements in quality of life.
The FDA Digital Health Software Precertification Program represents a feasible solution to regulate software classified as a medical device.
Possessing a high level of insight into one's disorder can negatively affect life satisfaction in schizophrenia.
More Articles by Brandon May
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Clinician Insight: Exploring the Link Between Bipolar Disorder and Binge Eating Disorder
- #MeToo: Helping Victims Cope With Sexual Harassment
- Association Between Psychosis and Development of Dementia in Older Men
- Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids
- Personality Functioning Associated With Global Functioning in Bipolar Disorder I
- Nutritional Influences on Bipolar Disorder in Children
- Triiodothyronine in the Treatment of Bipolar Depression
- Old Challenges and New Directions in Managing Tardive Dyskinesia
- Similar Rates of Childhood Trauma in Schizophrenia and Substance Use Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Childhood Insulin Resistance Associated With Later Psychosis
- Lamotrigine Similar to Placebo in Treating Borderline Personality Disorder
- Glucocorticoids May Increase Risk of Developing Schizophrenia Spectrum Disorder
- Predictors, Incidence of Long-term Use of Benzodiazepines, Z-Drugs in Bipolar Disorder
- Cardiometabolic Dysregulation Associated With Cognitive Decline Mediated by Depression